Article

Management of progressive multiple sclerosis (MS) is one of the main challenges
of the new century. Based on our knowledge of pathophysiology, three therapeutic
strategies are proposed: anti-inflammatory (ocrelizumab, siponimod...) ;
remyelinating (opicinumab) ; and neuroprotective (high-dose biotin, ibudilast,
simvastatin...). Nevertheless, despite recent promising positive clinical trials,
new methodological approaches for therapeutic protocols with adaptable outcomes
to assess progression are still needed.
CI - Copyright (c) 2018 Elsevier Masson SAS. All rights reserved.

Langue : ANGLAIS